产品
编 号：F342272
分子式：C26H29Cl2N5O3
分子量：530.45
分子式：C26H29Cl2N5O3
分子量：530.45
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
112
In-stock
5mg
225
In-stock
10mg
360
In-stock
50mg
680
In-stock
100mg
880
In-stock
200mg
1440
In-stock
结构图
CAS No: 380843-75-4
产品详情
生物活性：
Bosutinib is an orally active Src/Abl tyrosine kinase inhibitor with IC50 of 1.2 nM and 1 nM, respectively.
体内研究：
Bosutinib (oral gavage; 75 mg/kg twice daily or 150 mg/kg once daily) has activity against human KU812 xenografts in nude mice. Bosutinib (150 mg/kg; once daily, 5 days weekly) has activity against syngeneic Bcr-Abl WT and mutantBa/F3 xenografts.Animal Model:KU812CM L xenograft model
Dosage:75 mg/kg twice daily or 150 mg/kg once daily
Administration:Bosutinib (oral gavage; 75 mg/kg twice daily or 150 mg/kg once daily)
Result:Had the therapeutic activity and produced a dose- and schedule-dependent weight loss.
Animal Model:Syngeneic Bcr-Abl WT and mutant Ba/F3 xenografts
Dosage:150 mg/kg
Administration:Bosutinib (150 mg/kg; once daily, 5 days weekly)
Result:Decreased the rate of tumor growth and prolonged event-free survival of mice.
体外研究：
Bosutinib (SKI-606) is an active inhibitor of Bcr-Abl in several chronic myelogenous leukemia cell lines, with IC50 values in the low nanomolar range.
Bosutinib is an orally active Src/Abl tyrosine kinase inhibitor with IC50 of 1.2 nM and 1 nM, respectively.
体内研究：
Bosutinib (oral gavage; 75 mg/kg twice daily or 150 mg/kg once daily) has activity against human KU812 xenografts in nude mice. Bosutinib (150 mg/kg; once daily, 5 days weekly) has activity against syngeneic Bcr-Abl WT and mutantBa/F3 xenografts.Animal Model:KU812CM L xenograft model
Dosage:75 mg/kg twice daily or 150 mg/kg once daily
Administration:Bosutinib (oral gavage; 75 mg/kg twice daily or 150 mg/kg once daily)
Result:Had the therapeutic activity and produced a dose- and schedule-dependent weight loss.
Animal Model:Syngeneic Bcr-Abl WT and mutant Ba/F3 xenografts
Dosage:150 mg/kg
Administration:Bosutinib (150 mg/kg; once daily, 5 days weekly)
Result:Decreased the rate of tumor growth and prolonged event-free survival of mice.
体外研究：
Bosutinib (SKI-606) is an active inhibitor of Bcr-Abl in several chronic myelogenous leukemia cell lines, with IC50 values in the low nanomolar range.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备